Juan J. Gomez-Reino
University of Santiago de Compostela
Publications 373
Published on Mar 1, 2019in Arthritis & Rheumatism 7.87
Cristina Regueiro3
Estimated H-index: 3
Luis Rodriguez-Rodriguez18
Estimated H-index: 18
+ 18 AuthorsAna M. Ortiz18
Estimated H-index: 18
Source Cite
Published on Mar 1, 2019in Rheumatology International 1.95
Maria Victoria Hernández19
Estimated H-index: 19
Carlos Sánchez-Piedra4
Estimated H-index: 4
+ 12 AuthorsMc Castro-Villegas5
Estimated H-index: 5
The retention rate of a biological drug (percentage of patients remaining on treatment over time) provides an index of a drug’s overall effectiveness. The golimumab retention rate as first-line biological therapy was high in clinical trial extensions lasting 5 years. Real-world studies also indicate good retention rates but have been of shorter duration. The probability of retention with golimumab treatment was assessed, as any line of anti-tumor necrosis factor-alpha therapy, for up to 5 years ...
Source Cite
Published on Apr 3, 2019in Expert Review of Clinical Immunology 3.44
M. Pombo-Suarez9
Estimated H-index: 9
Juan J. Gomez-Reino63
Estimated H-index: 63
ABSTRACTIntroduction: Rheumatoid arthritis (RA) is a complex disease in which different mechanisms are involved. Studies suggest a key role for aberrant pathways of T-cell activation in the initiation and perpetuation of disease. Abatacept is a fusion protein composed of the Fc region of the immunoglobulin G1 (IgG1) fused to the extracellular domain of cytotoxic T lymphocyte-associated antigen (CTLA4). It has the ability to modulate T-cell activation by interfering with co-stimulation of these c...
Source Cite
Published on Jun 1, 2018in Annals of the Rheumatic Diseases 12.35
Peter Nash38
Estimated H-index: 38
(University of Queensland),
Kamal Ohson3
Estimated H-index: 3
(Memorial University of Newfoundland)
+ 6 AuthorsJacob Aelion11
Estimated H-index: 11
Background ACTIVE is the first apremilast (APR) study to demonstrate onset of response to APR starting at Week 2 in biologic-naive subjects with psoriatic arthritis (PsA) who may have had exposure to 1 prior conventional disease-modifying anti-rheumatic drug. Objectives To determine the efficacy and safety of APR through Week 104 in the ACTIVE study. Methods Subjects were randomised (1:1) to receive APR 30 mg BID or placebo (PBO) for 24 weeks; thereafter, all subjects received active treatment w...
Source Cite
Published on Jun 1, 2018in RMD Open
Dafna D. Gladman99
Estimated H-index: 99
(Toronto Western Hospital),
Arthur Kavanaugh73
Estimated H-index: 73
(University of California, San Diego)
+ 10 AuthorsLichen Teng3
Estimated H-index: 3
Objective The Psoriatic Arthritis Long-term Assessment of Clinical Efficacy (PALACE) clinical trial programme findings demonstrated that apremilast, an oral phosphodiesterase 4 inhibitor, is effective for treating psoriatic arthritis (PsA). Enthesitis and dactylitis are difficult-to-treat features of PsA leading to disability and affecting quality of life. PALACE 1, 2 and 3 data were pooled to assess the efficacy of apremilast on enthesitis and dactylitis outcomes in patients with these conditio...
Source Cite
Published on Dec 1, 2018in Arthritis Research & Therapy 4.27
Juan José Bethencourt Baute2
Estimated H-index: 2
(Hospital Universitario de Canarias),
Carlos Sánchez-Piedra4
Estimated H-index: 4
+ 15 AuthorsVictoria Hernández1
Estimated H-index: 1
Biologic therapy has changed the prognosis of patients with juvenile idiopathic arthritis (JIA). The aim of this study was to examine the pattern of use, drug survival, and adverse events of biologics in patients with JIA during the period from diagnosis to adulthood. All patients included in BIOBADASER (Spanish Registry for Adverse Events of Biological Therapy in Rheumatic Diseases), a multicenter prospective registry, diagnosed with JIA between 2000 and 2015 were analyzed. Proportions, means, ...
Source Cite